Corporate News
Page 6
Apr 24, 2019
REPROCELL and Hanugen to custom manufacture clinical grade oligos for gene therapy
REPROCELL India and Hanugen Therapeutics have announced the launch of their custom manufacture offering for synthesis of milli molar scale clinical grade oligonucleotides for gene therapy.
Apr 08, 2019
REPROCELL USA Inc. Achieves Quality Management ISO9001:2015 Certification
Find out about REPROCELL USA's recently achieved ISO9001:2015 accreditation. demonstrating its ability to consistently meet customer requirements
Mar 14, 2019
UK Government’s science and innovation audit highlights REPROCELL’s work in precision medicine
Wave 3 of the UK Government’s science and innovation audits (SIAs) have been published today, identifying a number of strengths in different industries across the country — including precision medicine innovation in Scotland, led by the University of Glasgow.
Mar 12, 2019
REPROCELL join Medicines Discovery Catapult’s Virtual R&D network to accelerate drug development
REPROCELL has joined Medicines Discovery Catapult’s Virtual R&D platform – a unique national network of consultants, private sector CROs, expert labs and public sector centres of excellence, providing medicines discovery expertise, services and virtual programme management.
Feb 28, 2019
REPROCELL Inc. forms joint venture with Fox Chase Cancer Center to begin operations on biosample repositories
REPROCELL Inc. and Fox Chase, Ltd., have formed a joint venture to begin operations of multi-site biosample repository facilities globally.
Feb 01, 2019
Appointment of New Distributor in China
The REPROCELL group has signed non-exclusive distributorship agreement with RUITAI Biotechnology (Shanghai) Ltd to distribute REPROCELL’s group products in China.
Oct 10, 2018
ROSLINCT and REPROCELL awarded £1.2 million from Innovate UK for clinical-grade stem cell production
Learn more about the partnership between REPROCELL and ROSLINCT aiming to improve efficiency of induced pluripotent stem cell production
Oct 09, 2018
REPROCELL announces the launch of a cutting-edge iPS cell genome editing service utilizing next-generation CRISPR/Cas9 technology: SNIPER
REPROCELL announced today we have launched a cutting-edge genome editing service utilizing next-generation CRISPR/Cas9 technology, called SNIPER. This service is offered in collaboration with GenAhead Bio Inc. (Kanagawa, Japan).
Aug 01, 2018
Steminent Announces Japan partner REPROCELL has PMDA Approval of CTN for Phase II Trial of Stemchymal® SCA in the Treatment of Spinocerebellar Ataxia in Japan
Read the Japan Pharmaceuticals and Medical Device Agency's announcement that REPROCELL has acheived PMDA Approval of CTN for Phase II Trial of Stemchymal
Jun 21, 2018
Human Tissue Experts REPROCELL Launch New Customized Primary Cell Isolation Services
Read more about how REPROCELL’s BioServe and Biopta tissue procurement networks have combined to create a new service isolating human primary cells.
Jun 13, 2018
REPROCELL’s footprint extends to serve life sciences in India
Learn more about REPROCELL India's expansion into the life sciences industry through the integration of Oligonucleotide Services and Next Generation Sequencing
Apr 26, 2018
Acquisition of BioServe Biotechnologies India Pvt. Ltd.
REPROCELL announces that it has acquired Bioserve biotechnologies, further expanding REPROCELL's portfolio of service offerings
Apr 18, 2018
REPROCELL’s Dr David Bunton on April 2018 Trade Mission to China with Scottish First Minister Nicola Sturgeon
REPROCELL Europe’s CEO, Dr David Bunton, was part of the trade mission to China undertaken by the Scottish First Minister, the Rt. Hon. Nicola Sturgeon MSP, 9-13 April 2018.
Apr 06, 2018
Derek Mackay, SNP Cabinet Secretary for Finance and the Constitution, visits REPROCELL Europe, Glasgow
Read about REPROCELL's visit from Derek Mackay, the Scottish National Party’s Cabinet Secretary for Finance and the Constitution, on 05 April 2017
Mar 21, 2018
REPROCELL’s David Bunton addresses the Scottish Parliament
Discussing how sectors, such as life science, are affected by Scotland’s economic performance and what actions are required to make the economy more inclusive, innovative and international. Topics include key factors in company success, SME’s and government partnership.
Mar 14, 2018
Patient-derived tumor organoids recapitulate clinical treatments
REPROCELL is currently working to develop a highly predictive three-dimensional (3D) human micro-intestine model that can be used to test new drugs for the treatment of IBD and gastrointestinal cancers.
Jan 24, 2018
REPROCELL’s Prof Stefan Przyborski to chair the SMi 2nd Annual Conference on 3D Cell Culture – London UK, 21-22 February 2018
Read the announcement that REPROCELL Europe’s CSO Prof Stefan Przyborski will chair the first day of the 3D Cell Culture conference.
Jan 19, 2018
Formation of human tissue to improve drug testing and reduce animal research
REPROCELL’s Alvetex, a scaffold for 3D cell culture and bioengineered tissue models, is in the Durham University (UK) News yesterday.
Jan 15, 2018
REPROCELL Launches New Global Website
Today, REPROCELL rolled out its new comprehensive global website demonstrating the synergies and power of the full portfolio of products and services.
Nov 29, 2017
REPROCELL Announces Research Collaboration with Q Therapeutics and Dr Mahendra Rao
Learn more about REPROCELL's collaborative research agreement with Q therapeutics to develop new iPS Cell therapies for central nervous system diseases